Literature DB >> 30471331

Therapy resistance mediated by cancer stem cells.

Teresa Bernadette Steinbichler1, József Dudás1, Sergej Skvortsov2, Ute Ganswindt3, Herbert Riechelmann1, Ira-Ida Skvortsova4.   

Abstract

Cancer stem cells (CSC) possess abilities generally associated with embryonic or adult stem cells, especially self-renewal and differentiation. The CSC model assumes that this subpopulation of cells sustains malignant growth, which suggests a hierarchical organization of tumors in which CSCs are on top and responsible for the generation of intratumoral heterogeneity. Effective tumor therapy requires the eradication of CSC as they can support regrowth of the tumor resulting in recurrence. However, eradication of CSC is difficult because they frequently are therapy resistant. Therapy resistance is mediated by the acquisition of dormancy, increased DNA repair and drug efflux capacity, decreased apoptosis as well as the interaction between CSC and their supporting microenvironment, the CSC niche. This review highlights the role of CSC in chemo- and radiotherapy resistance as well as possible ways to overcome CSC mediated therapy resistance.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; DNA repair; Dormancy; EMT; Stem cell niche

Mesh:

Substances:

Year:  2018        PMID: 30471331     DOI: 10.1016/j.semcancer.2018.11.006

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  82 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  Kinins in Glioblastoma Microenvironment.

Authors:  Mona N Oliveira; Barbara Breznik; Micheli M Pillat; Ricardo L Pereira; Henning Ulrich; Tamara T Lah
Journal:  Cancer Microenviron       Date:  2019-08-16

3.  The Concomitant Expression of Human Endogenous Retroviruses and Embryonic Genes in Cancer Cells under Microenvironmental Changes is a Potential Target for Antiretroviral Drugs.

Authors:  Alessandro Giovinazzo; Emanuela Balestrieri; Vita Petrone; Ayele Argaw-Denboba; Chiara Cipriani; Martino Tony Miele; Sandro Grelli; Paola Sinibaldi-Vallebona; Claudia Matteucci
Journal:  Cancer Microenviron       Date:  2019-11-05

Review 4.  Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer.

Authors:  Kuancan Liu; Tingting Zhao; Junkai Wang; Yunyun Chen; Rui Zhang; Xiaopeng Lan; Jianwen Que
Journal:  Cancer Lett       Date:  2019-05-21       Impact factor: 8.679

Review 5.  EMT and Cancer: More Than Meets the Eye.

Authors:  Rik Derynck; Robert A Weinberg
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

Review 6.  Mechanism of interaction between autophagy and apoptosis in cancer.

Authors:  Shreya Das; Nidhi Shukla; Shashi Shekhar Singh; Sapana Kushwaha; Richa Shrivastava
Journal:  Apoptosis       Date:  2021-09-12       Impact factor: 4.677

7.  CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway.

Authors:  Ying Ren; Yue Kai Gu; Zhen Li; Guang Zi Xu; Yang Meng Zhang; Min Xin Dong; Ying Wang; Xi Bing Zhou
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

8.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

Review 9.  Upregulation of pro-tumor nitric oxide by anti-tumor photodynamic therapy.

Authors:  Albert W Girotti; Jonathan M Fahey
Journal:  Biochem Pharmacol       Date:  2019-12-11       Impact factor: 5.858

Review 10.  Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.

Authors:  Joshua J Meeks; Hikmat Al-Ahmadie; Bishoy M Faltas; John A Taylor; Thomas W Flaig; David J DeGraff; Emil Christensen; Benjamin L Woolbright; David J McConkey; Lars Dyrskjøt
Journal:  Nat Rev Urol       Date:  2020-03-31       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.